Citation Impact
Citing Papers
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota
2012 StandoutScience
Twenty years of two‐dimensional electrophoresis: Past, present and future
1996
Hallmarks of Cancer: The Next Generation
2011 Standout
Endogenous human microRNAs that suppress breast cancer metastasis
2008 StandoutNature
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
2004 Standout
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
2004 Standout
Inflammation and cancer
2002 StandoutNature
Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
1995 StandoutNobel
Genes that mediate breast cancer metastasis to the brain
2009 StandoutNature
Metabolism of the Endocannabinoids, 2-Arachidonylglycerol and Anandamide, into Prostaglandin, Thromboxane, and Prostacyclin Glycerol Esters and Ethanolamides
2002
A Novel Mouse Model of Inflammatory Bowel Disease Links Mammalian Target of Rapamycin-Dependent Hyperproliferation of Colonic Epithelium to Inflammation-Associated Tumorigenesis
2009
Immunosuppressive networks in the tumour environment and their therapeutic relevance
2005 Standout
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
2002 Standout
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin–Yang interplay between inflammation and cancer
2010
Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity
2000
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis
2007 Nature
Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors
2014 StandoutNature
Cancer Metastasis: Building a Framework
2006 Standout
Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues
2002
Imaging in the era of molecular oncology
2008 StandoutNature
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
2005 Standout
Molecular Epidemiology: Insights Into Cancer Susceptibility, Risk Assessment, and Prevention
1996
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part I)
1998
Cancer Modeling in the Modern Era
2002
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor
2002
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
2005 Standout
Cyclooxygenase inhibitors – current status and future prospects
2001
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Nuclear factor-κB in cancer development and progression
2006 StandoutNature
Prostaglandin E2 Induces Hypoxia-inducible Factor-1α Stabilization and Nuclear Localization in a Human Prostate Cancer Cell Line
2002
Regulation of angiogenesis by hypoxia: role of the HIF system
2003 StandoutNobel
Conditional mouse models of sporadic cancer
2002
Angiogenesis in life, disease and medicine
2005 StandoutNature
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
2001
The mighty mouse: genetically engineered mouse models in cancer drug development
2006
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
The microenvironment of the tumour–host interface
2001 StandoutNature
Immunity, Inflammation, and Cancer
2010 Standout
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?
2003
Cytokines in cancer pathogenesis and cancer therapy
2004
Mouse Skin as a Model for Cancer Chemoprevention by Nonsteroidal Anti-Inflammatory Drugs
2003
Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)
1996 Standout
Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models
1996
Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention
2003
Chemoprevention of gastrointestinal cancer
1997
Molecular Damage in the Bronchial Epithelium of Current and Former Smokers
1997
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
2005 StandoutNature
Tobacco Smoke Carcinogens and Lung Cancer
1999 Standout
Paradoxical roles of the immune system during cancer development
2006 Standout
Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part II)
1998
Prostaglandin E2 Increases Growth and Motility of Colorectal Carcinoma Cells
2001
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
The Human Plasma Proteome
2002 Standout
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Cancer-related inflammation
2008 StandoutNature
Selenium in Cancer Prevention: Clinical Issues and Implications
2001
Proteomics to study genes and genomes
2000 StandoutNature
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
2006 Standout
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
2001
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
PRECLINICAL AND CLINICAL MODELS OF LUNG CANCER CHEMOPREVENTION
1998
Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.
2003
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
2006 StandoutScience
Molecular insights into cancer invasion: strategies for prevention and intervention.
1995
The Fourth DeWitt S. Goodman lecture. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention.
2000
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal.
2001
Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
2002
Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.
1995
Mass spectrometry-based proteomics
2003 StandoutNature
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
2003
Cyclooxygenase-2 Inhibitor Induces Apoptosis in Breast Cancer Cells in an In vivo Model of Spontaneous Metastatic Breast Cancer
2004
Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance?
2003
Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing.
2000
Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes
1997 StandoutScience
Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways.
2000
Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
2002
Functional Characterization of Cyclooxygenase-2 Polymorphisms
2001
Catalytic Asymmetric Protonation of Silyl Ketene Imines
2013 StandoutNobel
Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**
2021 StandoutNobel
Cyclooxygenase-2 Polymorphism
2002
Immune recognition and tumor protection
2002
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
2001
Organoselenium and Organotellurium Compounds: Toxicology and Pharmacology
2004 Standout
New agents for cancer chemoprevention
1996
Chemical Glycoproteomics
2016 StandoutNobel
Prevention--therapy--basic science and the resolution of the cancer problem.
1993
Mass Spectrometry and Protein Analysis
2006 StandoutScience
Works of Gary J. Kelloff being referenced
Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action
1993
The natural history of intraepithelial neoplasia: Relevance to the search for intermediate endpoint biomarkers
1992
Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam
1993
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION: Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder
1996
Recent Results in Preclinical and Clinical Drug Development of Chemopreventive Agents at the National Cancer Institute
1993
Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention
1993
Strategy and planning for chemopreventive drug development: Clinical development plans
1994
Effects of oltipraz and related chemoprevention compounds on gene expression in rat liver
1995
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
2001
Aromatase inhibitors as potential cancer chemopreventives.
1998
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
2000
Risk biomarkers and current strategies for cancer chemoprevention
1996
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
2000
Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
1994
Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.
1996
Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice.
1999
Enhancement of experimental colon cancer by genistein.
1997
Apoptosis, cell replication, and Western-style diet-induced tumorigenesis in mouse colon.
1996